---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009695"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:48:30.177841+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner

## Summary
- Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.
- Entered strategic partnership with specialty manufacturer for commercial launch of PF614 and PF614-MPAR.
- PF614-MPAR-102 interim data show overdose protection at 100 mg dose; study continues at higher doses.
- FDA feedback on PF614 phase 3 design received; enrollment expected Q2 2025; NDA submission targeted for 2026.

## SEC filing metadata
- accession: 0001493152-25-009695
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315225009695/0001493152-25-009695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315225009695/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009695
- JSON: https://secwatch.observer/filing/0001493152-25-009695.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009695.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.